Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014)
Measurable disease, as defined by at least 1 of the following:
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Upapproximately 2 years
Awards & highlights
No Placebo-Only Group
MagnetisMM-9 Trial Summary
This trial is testing the safety of a new dosing method for a medication used to treat myeloma. The study will also look at how effective the medication is at different doses and how often it should be given.
Eligible Conditions
- Multiple Myeloma
MagnetisMM-9 Trial Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowSelect...
You have been diagnosed with multiple myeloma according to specific criteria.
Select...
You have a condition that can be measured to track changes during the study.
Select...
You have a high level of M-protein in your blood.
Select...
You have more than 200 milligrams of M-protein in your urine over a 24-hour period.
Select...
Your blood test shows high levels of a specific type of protein and an abnormal ratio of different types of proteins.
Select...
You have not responded to at least one specific type of medication called an IMiD.
Select...
You have not responded to at least one specific type of medication.
Select...
You have not responded to at least one anti-CD38 antibody treatment.
Select...
You have not responded well to the last treatment for myeloma, or the myeloma has come back after treatment.
Select...
You are able to perform everyday activities without any major limitations.
Select...
Any side effects from previous treatment have either gone away or are very mild.
MagnetisMM-9 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of participants with overall response rate (ORR) per International Myeloma Working Group (IMWG) criteria (Part 3).
Proportion of participants with Grade 2 or higher Cytokine Release Syndrome (CRS) (Part 1 and 2)
Secondary outcome measures
Complete Response Rate
Duration of complete response rate
Duration of response
+11 moreSide effects data
From 2013 Phase 4 trial • 122 Patients • NCT014749152%
Cerebrospinal fluid leak
2%
Fever
2%
Deep Vein Thrombosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ondansetron
Aprepitant
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
MagnetisMM-9 Trial Design
5Treatment groups
Experimental Treatment
Group I: Part 3Experimental Treatment1 Intervention
To explore the combination with dexamethasone
Group II: Part 2CExperimental Treatment1 Intervention
To explore higher dose intensity
Group III: Part 2BExperimental Treatment1 Intervention
Dose expansion
Group IV: Part 2AExperimental Treatment1 Intervention
Dose determination
Group V: Part 1Experimental Treatment1 Intervention
Evaluation of step-up priming dosing
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Elranatamab
2022
N/A
~650
Find a Location
Who is running the clinical trial?
PfizerLead Sponsor
4,513 Previous Clinical Trials
9,895,039 Total Patients Enrolled
31 Trials studying Multiple Myeloma
9,342 Patients Enrolled for Multiple Myeloma
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,435 Previous Clinical Trials
7,123,995 Total Patients Enrolled
23 Trials studying Multiple Myeloma
4,742 Patients Enrolled for Multiple Myeloma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a type of early stage multiple myeloma called "smoldering" multiple myeloma.You currently have a type of blood cancer called plasma cell leukemia that is not in remission.You have POEMS syndrome.You have amyloidosis.Criterion: You have Waldenström's macroglobulinemia.You currently have a serious infection like hepatitis, COVID-19, HIV, or other uncontrolled infections.You have had any other type of cancer in the past 3 years, except for certain types of skin cancer or very early stage cancers with low risk of coming back.You have received a specific type of treatment for your condition called anti-BCMA bispecific antibody or CAR-T cell therapy in the past.You have received a live weakened vaccine within the last 4 weeks before starting the trial.You are allergic to the study treatment or any of its ingredients, or you cannot handle the planned doses of corticosteroids.You have been diagnosed with multiple myeloma according to specific criteria.You have a condition that can be measured to track changes during the study.You have a high level of M-protein in your blood.You have more than 200 milligrams of M-protein in your urine over a 24-hour period.You have not responded to at least one specific type of medication called an IMiD.You have not responded to at least one specific type of medication.You have not responded to at least one anti-CD38 antibody treatment.You have not responded well to the last treatment for myeloma, or the myeloma has come back after treatment.You are able to perform everyday activities without any major limitations.Any side effects from previous treatment have either gone away or are very mild.You have signs of cancer in your brain or spinal cord.You had a stem cell transplant or have active GVHD within the last 12 weeks.Your blood test shows high levels of a specific type of protein and an abnormal ratio of different types of proteins.
Research Study Groups:
This trial has the following groups:- Group 1: Part 2C
- Group 2: Part 1
- Group 3: Part 2A
- Group 4: Part 2B
- Group 5: Part 3
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
In which areas can individuals access this clinical trial?
"34 medical centres are currently recruiting for this study, including Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy in Long Island City, MSK Westchester in Harrison, and MSK Basking Ridge in Basking Ridge. Multiple other locations also have enrolment spots available."
Answered by AI
How many individuals are participating in this medical research?
"Affirmative. Details on clinicaltrials.gov support that this medical trial is open for recruitment, with the original posting date of October 7th 2021 and most recent update dated November 21st 2022. 76 participants from 34 different sites are needed to complete this experiment."
Answered by AI
To what extent could Elranatamab be hazardous to human health?
"After thorough evaluation, we have determined that Elranatamab is a safe enough medication to receive an assessment of 2. This rating accounts for Phase 2 trial results which demonstrate safety but lack evidence in support of efficacy."
Answered by AI
Are there any opportunities for individuals to participate in this experiment?
"Affirmative. According to details on clinicaltrials.gov, this trial is actively seeking applicants; it was first listed on October 7th 2021 and has recently been updated as of November 21st 2022. The study is currently enrolling 76 people at 34 centers around the country."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger